

Maps



Kuopio was founded already in 1653, although official date is recognized as November 17, 1775. Kuopio is surrounded by water, lake Kallavesi, and several parts of the city have actually been built on islands.

Kuopio is known as a strong center of health, pharmacy, environment, food & nutrition, safety and welfare professions.

*Kuopio is known for its association with a national delicacy, Finnish fish pastry and the dialect of Savo, as well as the hill of Puijo and the Puijo tower. Besides being a very popular outdoor recreation area, Puijo serves also as a stage for a yearly World Cup *ski jumping competition**

Scientific and Organisation committee:

Kari Airenne
 Minna Kaikkonen
 Henna Karvinen
 Leena Lampinen
 Hanna Lesch
 Emilia Makkonen
 Ann-Marie Määttä
 Otto-Wilhelm Merten
 Mauro Mezzina
 Jere Pikkarainen
 Seppo Ylä-Herttuala (President)

Scientific Office and
 Conference-Course manager:

Mauro Mezzina
 European Association for Scientific Career Orientation
 47, Avenue Reille - 75014 Paris, France
 phone: +33 1 53 80 29 63
 mobile: +33 6 85 07 69 05
 Email: mezzina@easco.org

Other partners and sponsors: *institutions who are employers of speakers & organisers and/or support the course with grants, equipment and materials*



Advanced symposium and EMBO practical course:

Viral Vectors in Gene Therapy Applications & Novel Production Methods

August 26th – September 4th, 2010
 Kuopio, Finland

www.KuopioEMBOlabcourse.easco.org



Dear Colleagues

With the 1st EMBO Eurolabcourse in Evry (F) in 2002, we started a series of courses on gene therapy with a new training format which combines a symposium open to all with a practical course for 25 participants selected on application. This format allows maximal interactivity between the participants coming from research institutions of academia and industry, health organizations, regulatory agencies and patients' associations from many countries worldwide.

The course will be held at the University of Eastern Finland, located in Kuopio, Finland and offers a complete review of knowledge and technology on adeno-associated-, baculovirus- and lentiviral-based vectors for gene therapy.

Although the registrations for the EMBO practical course are now closed there is still time to **join the symposium** and come listen for the world-renowned experts of the scientific community. **This year the course is particularly interesting since we received already registrations of participants from 30 countries!**

We look forward to welcoming you in Kuopio in August 2010.

Hanna Lesch
Senior research scientist
at Ark Therapeutics

Mauro Mezzina
Research director of CNRS
Course general manager

Seppo Ylä-Herttuala
Director of Department of Biotechnology
and Molecular Medicine
President of the Scientific Committee

| AGENDA: | | Thursday 26th |
|------------------------|--|--|
| Loy VOLKMAN | | <i>History of baculovirus system</i> |
| Manuel CARRONDO | | <i>The European baculovirus research area: the BACULOGENES project</i> |
| Seppo YLÄ-HERTTUALA | | <i>Viral Vectors and Gene Therapy</i> |
| Loy VOLKMAN | | <i>Biology of the baculovirus system</i> |
| Jürgen A. KLEINSCHMIDT | | <i>Biology of the AAV vector system – an overview</i> |
| Olivier DANOS | | <i>Biology of the LV vector system – an overview</i> |
| Maija VIHINEN-RANTA | | <i>Nuclear import and intranuclear dynamics of parvoviruses and baculoviruses</i> |
| Kari AIRENNE | | <i>Engineering baculoviruses for enhanced gene delivery</i> |
| Josh GRIEGER | | <i>Optimizing AAV vectors for gene delivery</i> |
| Richard J. SAMULSKI | | <i>Optimizing AAV vectors for gene delivery</i> |
| Mary COLLINS | | <i>New generation lentiviral vectors</i> |
| | | Friday 27th |
| Monique VAN OERS | | <i>Tailoring the baculovirus expression system for recombinant protein and virus-like particle production</i> |
| Robert M. KOTIN | | <i>AAV vectors production using baculovirus - Comparison with traditional methods</i> |
| Yu-Chen HU | | <i>Baculovirus-mediated gene delivery for tissue regeneration</i> |
| Workshop (A. Kamen) | | <i>International Efforts for Recombinant Baculovirus Reference Material</i> |
| | | <i>From education to the innovation for development of gene therapy products</i> |
| Round Table I | | Kalervo VÄÄNÄNEN: <i>The role of UEF in the education, research and innovation in Kuopio Science Park</i> <i>The state-of-the-art of the development of GT tools in Kuopio and EU (Ark Therapeutics), in USA (Lentigen) and in China (Telebio) + other SMEs</i> |
| | | Saturday 28th |
| Jeffrey CHAMBERLAIN | | <i>Viral-mediated gene therapy for muscular dystrophies</i> |
| Bjarne UDD | | <i>Diagnostic, transgenic and translational medicine of muscular dystrophies</i> |
| Liliane TENENBAUM | | <i>Recombinant AAV-mediated gene delivery to the central nervous system</i> |
| Richard J. SAMULSKI | | <i>Application of AAV vectors for the treatment of cardiovascular diseases</i> |
| Alessandro AIUTI | | <i>Development of lentiviral gene therapy for SCID</i> |
| Boro DROPULIC | | <i>Lentiviral vectors</i> |
| Odile COHEN-HAGUENAUER | | <i>Integrating activities and sustainability of lentiviral vectors</i> |
| Robert MOHRENWEISER | | <i>Vaccine & Viral Vector Manufacturing - Strategies for the future</i> |
| Manuel CARRONDO | | <i>Advances in the purification of baculoviruses: implications for enveloped viruses</i> |
| Robert M. KOTIN | | <i>Strategies for manufacturing for gene therapy applications</i> |
| J. Fraser WRIGHT | | <i>Purification and characterization of AAV-based vectors for use in clinical studies</i> |
| Amine KAMEN | | <i>Efficient manufacturing of viral vectors using the large scale transfection technology</i> |
| Otto-Wilhelm MERTEN | | <i>Advances in the large scale production and purification of LV vectors</i> |
| | | Sunday 29th |
| Paula ALVES | | <i>Development of quality control methods for baculovirus vectors</i> |
| Maria-A. ZANTA-BOUSSIF | | <i>Quality controls for AAV vectors: efficacy and safety consideration</i> |
| Giuliana VALLANTI | | <i>Development and validation of analytical methods for lentiviral vectors for clinical applications</i> |
| Eugenio MONTINI | | <i>In vivo assays to address the genotoxic potential of gene therapy vectors</i> |
| | | <i>From the bench to the bed side: Regulations and Ethics</i> |
| Round Table II | | Robert SHAW and Tiina PALOMÄKI <i>Clinical development, regulations & European concerted actions</i> Raymond SPIER <i>Ethics & gene therapy</i> |
| Frederic BUSHMAN | | <i>Closing lecture: Future prospect of viral gene therapy tools</i> |

Inscription fees:

Symposium

26 -29 August 2010

300 € ⁽¹⁾

Deadlines:

Registrations and abstract submission
for the **symposium only**:

June 30th, 2010

For oral communication

July 31st, 2010

For poster presentation

Registrations for the **Symposium and EMBO practical course**:

Closed

For more information on the scientific programme,
registrations, venue, sponsoring...:
www.KuopioEMBOlabcourse.easco.org

⁽¹⁾ Includes course material, welcome cocktail, lunches and coffee.
Additional 50 € must be paid by participants who wish to attend the social dinner at Rauhanlahti relay